Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

Inclusion Criteria: * Confirmed diagnosis of multiple myeloma less than 12 months since initiation of systemic therapy * Age ≥60 years at time of transplantation * KPS 70-100% * Recovery from complications of prior therapy Exclusion Criteria: * Diagnosis other than multiple myeloma * Chemotherapy or radiotherapy within 8 days of initiating treatment in this study * Prior dose-intense therapy within 56 days of initiating treatment in this study * Uncontrolled bacterial, viral, fungal or parasitic infections * Uncontrolled CNS metastases * Known amyloid deposition in heart * Organ dysfunction * LVEF \<40% or cardiac failure not responsive to therapy * FVC, FEV1 or DLCO \< 40% of predicted and/or receiving supplementary continuous oxygen * Evidence of hepatic synthetic dysfunction or total bilirubin \> 2x or AST \> 3x ULN * Measured creatinine \< 20ml/min * Sensory peripheral neuropathy grade 4 within 14 days of enrollment * Karnofsky score \< 70% * Life expectancy limited by other co-morbid illnesses